Related Experiment Video
Updated: Dec 13, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study
Tian-Yuan Xiong1, Fang-Yang Huang1, Qi Liu1
1Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Insights
Hypertension is a common comorbidity in COVID-19 patients and significantly increases the risk of adverse outcomes, including ICU admission and death. Anti-hypertensive therapies did not appear to influence patient prognosis in this study.
Area of Science:
- Infectious Diseases
- Cardiology
- Critical Care Medicine
Background:
- Comorbidities are frequently observed in patients with coronavirus disease 2019 (COVID-19).
- The clinical significance of these comorbidities in COVID-19 patients requires further elucidation.
Purpose of the Study:
- To investigate the prevalence of comorbidities among COVID-19 patients.
- To characterize the clinical implications and prognostic impact of comorbidities in COVID-19.
Main Methods:
- Retrospective multi-center study of 472 COVID-19 patients admitted between January 16th and March 10th, 2020.
- Composite endpoint defined as intensive care unit (ICU) admission, mechanical ventilation, or death.
- Multivariate logistic regression analysis to identify independent predictors of the composite endpoint.
Main Results:
- Hypertension was present in 15.0% of patients and was independently associated with an increased risk of the composite endpoint (OR 2.82).
- Hypertensive patients showed significantly higher rates of ICU admission, mechanical ventilation, and death compared to controls (p < .001).
- Older age, elevated neutrophil counts, and lactate dehydrogenase levels were also associated with adverse outcomes.
Conclusions:
- Antecedent hypertension is a significant comorbidity associated with poor prognosis in COVID-19 patients.
- Patients with hypertension face a substantially increased risk of severe outcomes and mortality.
- Current anti-hypertensive therapies did not demonstrate a significant impact on patient outcomes in this cohort.
Background:
Comorbidities are commonly seen in patients with coronavirus disease 2019 (COVID-19), but the clinical implication is not yet well-delineated. We aim to characterize the prevalence and clinical implications of comorbidities in patients with COVID-19.
Methods:
This is a retrospective multi-centre study involving patients admitted between January 16th and March 10th 2020. The composite endpoint was defined as the presence of at least one of the following, intensive care unit (ICU) admission, or the need for mechanical ventilation, or death.
Results:
A total of 472 consecutive cases admitted to 51 certified COVID-19 tertiary care hospitals were enrolled (median age was 43 [32-53.5] years and 53.0% were male). There were 101 (21.4%) patients presented with comorbidities, including hypertension (15.0%), diabetes mellitus (7.8%), coronary artery disease (2.6%), chronic obstructive pulmonary disease (1.3%) and cerebrovascular disease (1.9%). The composite endpoint occurred in 65 (13.8%) patients. Multivariate stepwise logistic regression analysis indicated that older age (odds ratio [OR] 1.39, 95% confidence interval (CI) 1.05-1.85, per 10-year increment), antecedent hypertension (OR 2.82, 95% CI 1.09-7.29), neutrophil counts (OR 1.33, 95% CI 1.14-1.56) and lactate dehydrogenase level (OR 1.01, 95% CI 1.00-1.01) were independently associated with the presence of composite endpoint. Hypertensive patients, compared with controls, had a greater chance of experiencing the composite endpoint (p < .001) and each individual endpoint, i.e. ICU admission (p < .001), mechanical ventilation (p < .001) and death (p = .012). In the stepwise regression analysis of anti-hypertensive medications, none of the therapy predicted the composite endpoint.
Conclusions:
Hypertension is a common comorbidity in patients with COVID-19 and associated with adverse outcomes. KEY MESSAGES Hypertension was identified as the comorbidity associated with the prognosis of COVID-19 in this retrospective cohort. Patients with hypertension could experience an increased risk of the composite endpoint. Anti-hypertensive therapy did not affect patient outcomes.
More Related Videos
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Coronary Artery Disease I: Introduction
Hypertension V: Nursing Management

